Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

1.

Systemic therapy for advanced carcinoid tumors: where do we go from here?

Paulson AS, Bergsland EK.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):785-93. Review.

PMID:
22679120
[PubMed - indexed for MEDLINE]
2.

Evolving treatment strategies for management of carcinoid tumors.

Strosberg J.

Curr Treat Options Oncol. 2013 Sep;14(3):374-88. doi: 10.1007/s11864-013-0246-4. Review.

PMID:
23892588
[PubMed - indexed for MEDLINE]
3.

[Carcinoid tumors].

Pregun I, Bodoky G, Rácz K, Tulassay Z.

Orv Hetil. 2010 Nov 14;151(46):1885-94. doi: 10.1556/OH.2010.29000. Review. Hungarian.

PMID:
21044939
[PubMed - indexed for MEDLINE]
Free Article
4.

Systemic therapeutic options for carcinoid.

Pavel M, Kidd M, Modlin I.

Semin Oncol. 2013 Feb;40(1):84-99. doi: 10.1053/j.seminoncol.2012.11.003. Review.

PMID:
23391116
[PubMed - indexed for MEDLINE]
5.

Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.

Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F.

Endocr Relat Cancer. 2008 Mar;15(1):257-66. doi: 10.1677/ERC-07-0202.

PMID:
18310292
[PubMed - indexed for MEDLINE]
Free Article
6.

Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy.

Kvols LK.

Am J Med. 1986 Dec 22;81(6B):49-55.

PMID:
2432781
[PubMed - indexed for MEDLINE]
7.

The evolving landscape of neuroendocrine tumors.

Bergsland EK.

Semin Oncol. 2013 Feb;40(1):4-22. doi: 10.1053/j.seminoncol.2012.11.013. Review. Erratum in: Semin Oncol. 2013 Apr;40(2):239.

PMID:
23391109
[PubMed - indexed for MEDLINE]
8.

mTOR inhibition, a potential novel approach for bronchial carcinoids.

Dong M, Yao JC.

Endocr Relat Cancer. 2011 Apr 28;18(3):C15-8. doi: 10.1530/ERC-10-0290. Print 2011 Jun.

PMID:
21427170
[PubMed - indexed for MEDLINE]
Free Article
9.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
[PubMed - indexed for MEDLINE]
10.

Inhibition of mTOR in carcinoid tumors.

Grozinsky-Glasberg S, Pavel M.

Target Oncol. 2012 Sep;7(3):189-95. doi: 10.1007/s11523-012-0225-x. Epub 2012 Aug 12. Review. Erratum in: Target Oncol. 2012 Sep;7(3):197.

PMID:
22886906
[PubMed - indexed for MEDLINE]
11.

[Pharmacologic therapy for neuroendocrine tumours].

Petrányi A, Bodoky G.

Orv Hetil. 2011 Mar 6;152(10):379-91. doi: 10.1556/OH.2011.29060. Review. Hungarian.

PMID:
21354954
[PubMed - indexed for MEDLINE]
12.

Neuroendocrine tumours of the small intestine.

Strosberg J.

Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):755-73. doi: 10.1016/j.bpg.2012.12.002. Review.

PMID:
23582917
[PubMed - indexed for MEDLINE]
13.

Activity of sunitinib in patients with advanced neuroendocrine tumors.

Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS.

J Clin Oncol. 2008 Jul 10;26(20):3403-10. doi: 10.1200/JCO.2007.15.9020.

PMID:
18612155
[PubMed - indexed for MEDLINE]
14.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

PMID:
21952069
[PubMed - indexed for MEDLINE]
15.

New treatment options for patients with advanced neuroendocrine tumors.

Chan JA, Kulke MH.

Curr Treat Options Oncol. 2011 Jun;12(2):136-48. doi: 10.1007/s11864-011-0148-2. Review.

PMID:
21437592
[PubMed - indexed for MEDLINE]
16.

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group.

Lancet. 2011 Dec 10;378(9808):2005-12. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25.

PMID:
22119496
[PubMed - indexed for MEDLINE]
17.

Management of advanced and/or metastatic carcinoid tumors: historical perspectives and emerging therapies.

Nandy N, Dasanu CA.

Expert Opin Pharmacother. 2013 Aug;14(12):1649-58. doi: 10.1517/14656566.2013.808623. Epub 2013 Jun 8. Review.

PMID:
23746075
[PubMed - indexed for MEDLINE]
18.

A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review).

Comaru-Schally AM, Schally AV.

Int J Oncol. 2005 Feb;26(2):301-9. Review.

PMID:
15645113
[PubMed - indexed for MEDLINE]
19.

Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.

Raderer M, Kurtaran A, Scheithauer W, Fiebiger W, Weinlaender G, Oberhuber G.

Oncology. 2001;60(2):141-5.

PMID:
11244329
[PubMed - indexed for MEDLINE]
20.

[Drug therapy of carcinoids of the gastrointestinal tract].

Engelbach M, Heusel CP, Kriegsmann J, Both S, Walgenbach S.

Zentralbl Chir. 2001 Sep;126(9):682-5. German.

PMID:
11699283
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk